Pinus Densiflora Bark Extract (PineXol) Decreases Adiposity in Mice by Down-Regulation of Hepatic De Novo Lipogenesis and Adipogenesis in White Adipose Tissue
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
PineXol, extracted from Korean red pine bark, has beneficial effects, such as antioxidant, antiinflammatory, and antilipogenic activities in vitro. We tested the hypothesis that PineXol supplementation could have anti-obesity effects on mice fed a high-fat diet (HFD). Four-weekold male C57BL/6 mice were fed normal chow (18% kcal from fat) or a HFD (60% kcal from fat). HFD-fed animals were also subjected to PineXol treatment at a dose of 10 or 50 mg/kg body weight (BW) (PX10 or PX50, respectively) body weight. The body weight and body fat mass in the PX50 group were statistically lower than those in the HFD group (p < 0.05 and p < 0.001, respectively). The concentration of hepatic triglycerides, total cholesterol, and lowdensity lipoprotein cholesterol were reduced in the PX50 group compared with the HFD group (p < 0.01). Acetyl CoA carboxylase (p < 0.01), elongase of very long chain fatty acids 6 (p < 0.01), stearoyl CoA desaturase 1 (p < 0.05), microsomal triglyceride transfer protein (p < 0.01), and sterol regulatory element-binding protein 1 (p < 0.05) were significantly decreased in the PX50 group compared with that in the HFD group. In white adipose tissue, CCAATenhancer- binding protein alpha (p < 0.05), peroxisome proliferator-activated receptor gamma (p < 0.001), and perilipin (p < 0.01) were decreased in the PX50 group compared with those in the HFD group. Therefore, the current study implies the potential of PineXol for the prevention and/or amelioration of obesity, in part by inhibition of both hepatic lipid synthesis and adipogenesis in white adipose tissue.
Abstract
PineXol, extracted from Korean red pine bark, has beneficial effects, such as antioxidant, antiinflammatory, and antilipogenic activities in vitro. We tested the hypothesis that PineXol supplementation could have anti-obesity effects on mice fed a high-fat diet (HFD). Four-weekold male C57BL/6 mice were fed normal chow (18% kcal from fat) or a HFD (60% kcal from fat). HFD-fed animals were also subjected to PineXol treatment at a dose of 10 or 50 mg/kg body weight (BW) (PX10 or PX50, respectively) body weight. The body weight and body fat mass in the PX50 group were statistically lower than those in the HFD group (p < 0.05 and p < 0.001, respectively). The concentration of hepatic triglycerides, total cholesterol, and lowdensity lipoprotein cholesterol were reduced in the PX50 group compared with the HFD group (p < 0.01). Acetyl CoA carboxylase (p < 0.01), elongase of very long chain fatty acids 6 (p < 0.01), stearoyl CoA desaturase 1 (p < 0.05), microsomal triglyceride transfer protein (p < 0.01), and sterol regulatory element-binding protein 1 (p < 0.05) were significantly decreased in the PX50 group compared with that in the HFD group. In white adipose tissue, CCAATenhancer- binding protein alpha (p < 0.05), peroxisome proliferator-activated receptor gamma (p < 0.001), and perilipin (p < 0.01) were decreased in the PX50 group compared with those in the HFD group. Therefore, the current study implies the potential of PineXol for the prevention and/or amelioration of obesity, in part by inhibition of both hepatic lipid synthesis and adipogenesis in white adipose tissue.
참고문헌 (39)
- Popkin BM, "The obesity epidemic is a worldwide phenomenon", Nutr. Rev, 56, pp.106~114 (1998)
- Das U, "Is obesity an inflammatory condition?", Nutrition, 17, pp.953~966 (2001)
- Kopelman PG, "Obesity as a medical problem", Nature, 404, pp.635~643 (2000)
- Biddinger SB, "From mice to men: insights into the insulin resistance syndromes", Annu. Rev. Physiol, 68, pp.123~158 (2006)
- Spiegelman BM, "Obesity and the regulation of energy balance", Cell, 104, pp.531~543 (2001)
- 강준구, "Anti-Obesity Drugs: A Review about Their Effects and Safety", Diabetes and Metabolism Journal, 36(1), pp.13~25 (2012), 대한당뇨병학회
- Ballinger A, "Orlistat: its current status as an anti-obesity drug", Eur. J. Pharmacol, 440, pp.109~117 (2002)
- Heal D, "Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from Damphetamine and D-fenfluramine", Int. J. Obes. Relat. Metab. Disord, 22, pp.S18~S28 (1998)
- Ioannides-Demos LL, "Safety of drug therapies used for weight loss and treatment of obesity", Drug Saf, 29, pp.277~302 (2006)
- Sergent T, "Phenolic compounds and plant extracts as potential natural anti-obesity substances", Food Chem, 135, pp.68~73 (2012)
- Maimoona A, "A review on biological, nutraceutical and clinical aspects of French maritime pine bark extract", J. Ethnopharmacol, 133, pp.261~277 (2011)
- Grimm T, "Antioxidant activity and inhibition of matrix metalloproteinases by metabolites of maritime pine bark extract (Pycnogenol)", Free Radic. Biol. Med, 36, pp.811~822 (2004)
- Packer L, "Antioxidant activity and biologic properties of a procyanidin-rich extract from pine (Pinus maritima) bark, Pycnogenol", Free Radic. Biol. Med, 27, pp.704~724 (1999)
- Virgili F, "Procyanidins extracted from Pinus maritima (Pycnogenol): scavengers of free radical species and modulators of nitrogen monoxide metabolism in activated murine RAW 264.7 macrophages", Free Radic. Biol. Med, 24, pp.1120~1129 (1998)
- Nocun M, "French maritime pine bark extract (Pycnogenol)reduces thromboxane generation in blood from diabetic male rats", Biomed. Pharmacother, 62, pp.168~172 (2008)
- Lee OH, "Pycnogenol inhibits l ipid a ccumulation i n 3T3- L1 a dipocytes w ith the modulation of reactive oxygen species (ROS) production associated with antioxidant enzyme responses", Phytother. Res, 26, pp.403~411 (2012)
- Canali R, "The antiinflammatory pharmacology of Pycnogenol in humans involves COX-2 and 5-LOX mRNA expression in leukocytes", Int. Immunopharmacol, 9, pp.1145~1149 (2009)
- Bayeta E, "Pycnogenol inhibits generation of inflammatory mediators in macrophages", Nutr. Res, 20, pp.249~259 (2000)
- Hasegawa N., "Stimulation of lipolysis by Pycnogenol", Phytother. Res, 13, pp.619~620 (1999)
- Hasegawa N., "Inhibition of lipogenesis by Pycnogenol", Phytother. Res, 14, pp.472~473 (2000)
- Ho JN, "Pycnogenol supplementation promotes lipolysis via activation of cAMPdependent PKA in ob", ob mice and primary-cultured adipocytes, 2014, pp.60, 429~435
- Ki Dong Kim, "Pinexol inhibits in vitro inflammatory biomarkers by blocking NF-κB signaling pathway and protects mice from lethal endotoxemia", Oriental Pharmacy and Experimental Medicine, 11(1), pp.61~70 (2011), 한의학연구소
- 이영준, "PineXol®의 항산화 및 지방세포 분화 억제 효과", 한국식품과학회지, 45(1), pp.97~103 (2013), 한국식품과학회[DOI]
- Saliou C, "Solar ultraviolet-induced erythema in human skin and nuclear factor-kappa-B–dependent gene expression in keratinocytes are modulated by a French maritime pine bark extract", Free Radic. Biol. Med, 30, pp.154~160 (2001)
- 황윤정, "적송제제(PineXol®)로 부터 Taxifolin과 (+)-Catechin, Procyanidin B1의 함량분석", 생약학회지, 47(3), pp.246~250 (2016), 한국생약학회
- Go G-W, "The combined hyperlipidemia caused by impaired Wnt-LRP6 signaling is reversed by Wnt3a rescue", Cell Metab, 19, pp.209~220 (2014)
- Michael SL, "Pretreatment of mice with macrophage inactivators decreases acetaminophen hepatotoxicity and the formation of reactive oxygen and nitrogen species", Hepatology, 30, pp.186~195 (1999)
- Krisko TI, "Genetic ablation of phosphatidylcholine transfer protein", starD2 in ob, Metabolism, pp.2017, 68[DOI]
- 김대덕, "국산 소나무껍질추출물(파인엑솔R)을 함유한 제제의 피부흡수 평가", Journal of Pharmaceutical Investigation, 37(6), pp.359~364 (2007), 한국약제학회
- Hsu CL, "Phenolic compounds: evidence for inhibitory effects against obesity and their underlying molecular signaling mechanisms", Mol. Nutr. Food Res, 52, pp.53~61 (2008)
- Sato M, "Dietary pine bark extract reduces atherosclerotic lesion development in male ApoE-deficient mice by lowering the serum cholesterol level", Biosci. Biotechnol. Biochem, 73, pp.1314~1317 (2009)
- Powell EE, "The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years", Hepatology, 11, pp.74~80 (1990)
- Trevaskis JL, "Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice", Am. J. Physiol. Gastrointest. Liver Physiol, 302, pp.G762~G772 (2012)
- Chen Y, "Liver-specific HBsAg transgenic mice are over-sensitive to poly(I: C)-induced liver injury in NK cell- and IFN-γ-dependent manner", J. Hepatol, 47, pp.183~190 (2007)
- Giannini E, "Progressive liver functional impairment is associated with an increase in AST", ALT ratio, 1999, pp.44, 1249~1253
- Devaraj S, "Supplementation with a pine bark extract rich in polyphenols increases plasma antioxidant capacity and alters the plasma lipoprotein profile", Lipids, 37, pp.931~934 (2002)
- Koch R., "Comparative study of Venostasin and Pycnogenol in chronic venous insufficiency", Phytother. Res, 16, pp.1~5 (2002)
- Guerrero L, "Serum metabolites of proanthocyanidinadministered rats decrease lipid synthesis in HepG2 cells", J. Nutr. Biochem, 24, pp.2092~2099 (2013)
- Yang J, "Pcynogenol inhibits adipogenesis and simulate antilipogenic effect in 3T3-L1 adipocytes", FASEB J, 24, pp.lb254~ (2010)